4.5 Review

Bladder Chemoprophylaxis Following Ureterorenoscopy in Patients with Upper Tract Urothelial Carcinoma

期刊

EUROPEAN UROLOGY FOCUS
卷 8, 期 5, 页码 1253-1255

出版社

ELSEVIER
DOI: 10.1016/j.euf.2021.07.007

关键词

Bladder chemoprophylaxis; Ureterorenoscopy; Upper tract urothelial carcinoma

向作者/读者索取更多资源

Kidney-sparing procedures for low-risk upper tract urothelial carcinoma (UTUC) have become elective indications. Ureterorenoscopy (URS) is commonly used for diagnosis and treatment, but it carries a higher risk of bladder seeding. This review examines the importance and scientific evidence for chemoprophylaxis after URS.
Kidney-sparing procedures for upper tract urothelial carcinoma (UTUC) have evolved from imperative to elective indications for management of low-risk disease. Ureterorenoscopy is the most common procedure for the diagnosis, treatment, and surveillance of UTUC. A notable consideration following ureterorenoscopy is the higher risk of downstream bladder seeding. Here we review the importance of and scientific evidence for chemoprophylaxis after ureterorenoscopy. Patient summary: For patients with low-risk cancer of the upper urinary tract, a procedure called ureterorenoscopy (URS) involving insertion of a thin telescope through the ureter and into the kidney is increasingly used for biopsy. URS increases the risk of cancer seeding in the bladder. We review evidence on the benefit of prophylactic bladder chemotherapy after URS. (c) 2021 European Association of Urology. Published by Elsevier B.V. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据